Intravenous Iron Drugs Market Size & Growth Analysis to 2030

The global intravenous iron drugs market size is projected to grow at a sustainable CAGR of over 8% during the forecast period 2021 to 2027. The increasing incidence of chronic renal disorder around the world is a primary factor to drive the market growth. Furthermore, the growing geriatric population, the increasing number of diabetic patients in the global population, and the increasing number of dialysis procedures are expected to fuel the market. The increasing cases of iron deficiency coupled with the government initiative and increasing investment in the healthcare sector are projected to boost the market. Moreover, the increasing need to prevent anemia in pregnant women along with improving maternal and birth outcomes and increasing awareness of healthcare and personal care is expected to propel the market.

Market Drivers:

Increasing prevalence of iron deficiency and related conditions: Iron deficiency is a common nutritional deficiency worldwide, affecting a significant portion of the population. Conditions such as iron deficiency anemia, chronic kidney disease, inflammatory bowel disease, and pregnancy-related anemia require intravenous iron supplementation for effective treatment. The rising prevalence of these conditions drives the demand for intravenous iron drugs.

Growing awareness about the benefits of intravenous iron therapy: There is a growing awareness among healthcare professionals and patients about the benefits of intravenous iron therapy compared to oral iron supplementation. Intravenous iron drugs provide a rapid and effective way to replenish iron stores in the body, especially in cases where oral iron is poorly tolerated or ineffective. This awareness leads to increased adoption of intravenous iron drugs as a preferred treatment option.

Advancements in iron drug formulations and delivery systems: Ongoing research and development efforts have resulted in advancements in iron drug formulations and delivery systems. Newer formulations offer improved safety, efficacy, and convenience for patients receiving intravenous iron therapy. For example, the development of iron carbohydrate complexes has enhanced the stability and tolerability of intravenous iron drugs, contributing to their increased use.

Aging population and increasing chronic disease burden: The aging population and the increasing burden of chronic diseases, such as chronic kidney disease and heart failure, contribute to the demand for intravenous iron drugs. These conditions are often associated with an increased risk of iron deficiency and anemia, requiring intravenous iron supplementation to address the underlying iron deficit. As the elderly population grows and chronic diseases become more prevalent, the demand for intravenous iron drugs is expected to rise.

Expansion of healthcare infrastructure and access to treatment: The expansion of healthcare infrastructure, particularly in emerging markets, improves access to diagnosis and treatment for iron deficiency and related conditions. Increased access to healthcare facilities and a growing number of patients seeking medical care contribute to the demand for intravenous iron drugs. Additionally, initiatives by governments and healthcare organizations to address anemia and improve maternal and child health further drive the market.

Strategic collaborations and partnerships: Collaborations and partnerships between pharmaceutical companies, healthcare organizations, and research institutions drive the development and commercialization of intravenous iron drugs. These collaborations allow for the sharing of expertise, resources, and clinical data, accelerating the development process and expanding market reach. Strategic alliances also facilitate the launch of innovative intravenous iron formulations and the exploration of new indications and treatment approaches.

Regulatory support and guidelines: Regulatory support and guidelines play a significant role in shaping the intravenous iron drugs market. Regulatory authorities provide approvals and establish guidelines for the development, manufacturing, and use of intravenous iron drugs. These regulations ensure product safety, efficacy, and quality, instilling confidence in healthcare professionals and patients. Regulatory support facilitates market entry for manufacturers and promotes the adoption of intravenous iron drugs in clinical practice.

Reimbursement policies and insurance coverage: Reimbursement policies and insurance coverage for intravenous iron drugs impact their market growth. Adequate reimbursement and insurance coverage enhance patient affordability and access to intravenous iron therapy. The inclusion of intravenous iron drugs in national reimbursement programs and insurance formularies encourages their usage and supports market expansion.

Market Outlook:

Market Insights:

The global intravenous iron drugs market is bifurcated into product, application, and geography. On the basis of product, the market is further segmented into iron dextran, iron sucrose, ferric carboxymaltose, and others. The ferric carboxymaltose sub-segment dominated the global market in 2020 and accounted to hold the largest revenue share around half of the market. The segment is also projected to maintain its dominance over the forecast period. The increasing application of ferric carboxymaltose coupled with its superior performance and reduced cost is a major factor that contributed the segment growth.

On the basis of application, the market is sub-segmented into chronic kidney disease, inflammatory bowel disease, cancer, and others. The chronic kidney diseases segment dominated the global intravenous iron drugs market in 2020 and accounted to hold a major market share of around one-third percent of the market. The increasing incidence of chronic kidney disease coupled with the high prevalence of iron deficiency of anima in CKD patients is a major factor driving the segment growth. On the other hand, the cancer segment is expected to grow at a fast growth rate over the forecast period.

To know more about the study, request sample papers

The intravenous iron drugs comprehensive study offers an in-depth analysis of industry trends, market size, competitive analysis, and market forecast – 2021 to 2027. Research Corridor report provides detailed premium insight into the global market and reveals the potential revenue streams, commercial prospects, market drivers, challenges, opportunities, issues, and events affecting the industry. In addition, the report has a dedicated section covering market forecasts and analysis for leading geographies, profiles of major companies operating in the market and expert opinion obtained from interviews with industry executives and experts from prominent companies.

The intravenous iron drugs market research report presents the analysis of each segment from 2018 to 2027 considering 2020 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2021 to 2027.

Historical & Forecast Period

• 2018-19 – Historical Year
• 2020 – Base Year
• 2021-2027 – Forecast Period

Market Segmentation:

By Product:

• Iron Dextran
• Iron Sucrose
• Ferric Carboxymaltose
• Others

By Application:

• Chronic Kidney Disease
• Inflammatory Bowel Disease
• Cancer
• Others

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Geographic Coverage:

Geographically, the intravenous iron drugs market report comprises dedicated sections centering on the regional market revenue and trends. The intravenous iron drugs market has been segmented on the basis of geographic regions into North America, Europe, Asia Pacific, and Rest of the World (RoW). The RoW segment consists of Latin America and the Middle East & Africa. The intravenous iron drugs market has been extensively analyzed on the basis of various regional factors such as demographics, gross domestic product (GDP), inflation rate, acceptance, and others. Intravenous iron drugs market estimates have also been provided for the historical years 2018 & 2019 along with forecasts for the period from 2021 – 2027.

Market Competition Assessment:

Some of the major players operating in the global intravenous iron drugs market are Daiichi Sankyo Company, Ltd., Vifor Pharma Management Ltd., Sanofi S.A., AMAG Pharmaceuticals, and Actavis, Inc. Companies are exploring markets by expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.

Key Companies:

• Daiichi Sankyo Company, Ltd.
• Vifor Pharma Management Ltd.
• Sanofi S.A.
• AMAG Pharmaceuticals
• Actavis, Inc.
• Pharmacosmos A/S
• Galenica Ltd.
• Shield Therapeutics Plc
• AbbVie Inc.
• American Regent, Inc.

Key Questions Answered by Intravenous Iron Drugs Market Report

• Global intravenous iron drugs market forecasts from 2021-2027
• Regional intravenous iron drugs market forecasts from 2021-2027 covering Asia-Pacific, North America, Europe, Middle East & Africa, and Latin America
• Country-level forecasts from 2021-2027 covering 15 major countries from the aforementioned regions
• Intravenous iron drugs submarket forecasts from 2021-2027 covering the market by product, by application, and geography
• Various industry models such as SWOT analysis, Value Chain Analysis pertaining to the intravenous iron drugs market
• Analysis of the key factors driving and restraining the growth of the global, regional and country-level intravenous iron drugs markets from 2021-2027
• Competitive Landscape and market positioning of top 10 players operating in the intravenous iron drugs market